Healthcare and Life Sciences Institute

Featured thought leadership

• 

  KPMG 2023 Healthcare and Life Sciences Investment Outlook

  Our 2023 Healthcare and Life Sciences Investment Outlook finds turbulence, and opportunity, in this post-pandemic marketplace.

• 

  Maximizing the potential of your generic portfolio strategy

  The Inflation Reduction Act may usher in a new era of growth for generics manufacturers.

• 

  KPMG healthcare industry technology insights report

  KPMG reports on the state of healthcare industry digital transformation, automation, artificial intelligence, and machine learning

• 

  KPMG life sciences technology insights report

  KPMG reports on the state of life sciences industry digital transformation, automation, artificial intelligence, and machine learning

• 

  Elevate the Provider Experience

  Unlocking value through enhanced payer-provider collaboration.

• 

  How to make the most of a downturn: Healthcare & Life Sciences

  Healthcare & life sciences firms that take strong action before a downturn—and invest during a slump—are more likely to outperform.

• 

  Opportunities abound even as risks rise: M&A trends in healthcare

  Acquirers and investors seek opportunities but tread more cautiously given economic uncertainty.

• 

  The convergence of the tech and healthcare sectors

  How tech, NFTs, cyber security, and talent are impacting the healthcare industry

• 

  Inflation Reduction Act: Healthcare provisions and impacts

  IRA will significantly impact prescription costs and insurance coverage for millions of Americans

• 

  Primary-care partnerships help payers boost patient outcomes

  Payers are increasingly partnering with primary-care organizations to improve patient outcomes.

• 

  The future of telehealth in the post-COVID-19 world

  How providers can win in the new digital health landscape

• 

  The Great Pandemic Unwind: Five Healthcare Issues to Watch

  Unwinding federal COVID-19 policies will have significant industry impacts.

• 

  FDA's Accelerated Approval Program: Accelerated Pathway for Reform?

  Reforms to FDA Accelerated Approval Program could include new confirmatory study requirements.

• 

  Healthcare boards look toward a very different future

  Healthcare boards shape strategies around consumerism, attrition, and ESG issues from climate change to boardroom diversity.

• 

  2022 Healthcare and Life Sciences Investment Outlook

  Our 2022 Healthcare and Life Sciences Investment Outlook offers a look into industry innovations with the greatest investor interest.

• 

  Healthcare anywhere, security everywhere

  Healthcare organizations need robust identity access management to provide the anytime, anywhere care that today’s patients demand.

• 

  Pharma leaders collaborate on supply-chain security framework

  KPMG spearheaded a cross-institutional team of pharma supply-chain leaders to develop a proprietary cybersecurity framework.

• 

  Perspectives from a payer-led pharmacy innovation lens

  Healthcare trends have created opportunities to strategically target pharmacy to make innovative and transformative impact.

• 

  ESG in healthcare is the new burning platform

  ESG in healthcare is a burning platform that includes telling your ESG story and making it synonymous with your brand.

• 

  Healthcare payors’ holistic approach to governance

  Healthcare payors should take a holistic approach to data governance to maximize valuable insights while minimizing risks.

• 

  How IT integration can drive growth after healthcare mergers

  By prioritizing patient-facing digital health systems during integration, healthcare providers can realize more value sooner.

• 

  Addressing social determinants through healthcare payment models

  This paper addresses how government can accelerate and fund the programs that directly address the social drivers of healthcare costs.

• 

  ESG Reporting in Healthcare: Driving a Connection to Health Outcomes

  Measuring Environmental, Social and Governance: Understanding connectivity to health outcomes and performance.

• 

  2021 Healthcare CEO Future Pulse

  200 health leaders were surveyed on workforce, digital health, partnerships, patient centricity, and delivery model changes.

• 

  Finding Value in Home Health and Hospice M&A

  How acquirers in home health and hospice can overcome complex market, regulatory, and operational challenges.

• 

  Reenvisioning the power of technology risk management in healthcare

  The rapid pace of technology disruption in the healthcare sector is bringing on new and more pervasive risks.

• 

  Thriving in an AI World: Healthcare insights

  Healthcare organizations have opportunities to use artificial intelligence to improve productivity, reduce risk, and save lives.

• 

  From payor to healthcare partner

  For payors evolving toward becoming “healthcare partners,” this paper covers six trends to watch in 2021.

• 

  Healthcare may be flying too close to the sun

  Learn how your healthcare organization can address the growing threat of more insidious cyber-security attacks.

• 

  American Rescue Plan Act of 2021: Healthcare Related Provisions

  The American Rescue Plan Act of 2021 expands healthcare coverage and provides pandemic funding.

• 

  2021 Healthcare and Life Sciences Investment Outlook

  Provides insights on how the political and regulatory environment, and market factors may impact investment decisions.

• 

  Medicare C&D Audit and Enforcement: A look back and look ahead

  Biden Administration could increase Medicare audit and enforcement in the years ahead: a review of the data

• 

  On the 2021 healthcare audit and compliance committee agenda

  Drawing on survey insights, we highlight the five areas that audit and compliance committee chairs rank as top priorities.

• 

  HIPAA privacy rule proposed modifications

  HHS proposed modifying HIPAA rules governing sharing, privacy, and security of personal health information

• 

  Most Favored Nation Drug Pricing Model final rule

  On November 20, 2020, the Centers for Medicare and Medicaid Services announced the Most Favored Nation Drug Pricing Model.

• 

  Revised Safe Harbor Protections for Prescription Drug Rebates

  HHS final rule requires pharmacy benefit managers to pass along prescription drug rebates to patients at the point of sale.

• 

  CMS and ONC proposed rule on electronic data exchange

  CMS and ONC proposed rule aims to improve health data exchange and streamline prior authorization

• 

  Health Plan Transparency in Coverage Final Rule

  HHS, Department of Labor, and Treasury finalized price transparency requirements for health plans set to take effect beginning in 2022.

• 

  COVID-19: Recovery and resilience in healthcare

  Global insights, practical advice, and tools to help healthcare leaders build and sustain a resilient new reality.

• 

  Connected Health: The new reality for healthcare

  High performing healthcare organizations need to evolve key capabilities and make technological investments to build on the digital momentum.

• 

  FDA final rule and guidance on importation of prescription drugs

  FDA finalized a rule and guidance allowing states to submit prescription drug importation proposals and manufacturers to re-label drugs for importation.

• 

  Price transparency: Requirements for hospitals and health plans

  Several price transparency requirements for hospitals and health plans take effect in 2021; stakeholders must prepare

• 

  Executive order on ‘Most-Favored-Nation’ drug pricing

  An Executive Order directs HHS rulemaking for “most favored nations” pricing for Medicare Part B and D drugs.

• 

  COVID-19: Telemedicine and tax

  As telemedicine accelerates, the need for greater tax clarity and updated guidance relating to virtual healthcare is evident.

• 

  Executive orders on prescription drug costs

  Four Executive Orders (EO) described as action to deliver lower prescription drug prices to American Patients.

• 

  The clinical trial conundrum

  Failing to resume clinical trials could present as many risks to certain patients as COVID-19.

• 

  Re-launching elective procedures

  An opportunity for medical device companies to shape their future customer base.

• 

  Healthcare providers: A break in the clouds

  Health systems’ future growth strategies must align with the ways in which COVID-19 has changed healthcare delivery.

• 

  KPMG Digital Lighthouse: Powering Life Sciences with advanced analytics

  The Life Sciences Industry is moving towards a dramatically different future based on a number of market drivers.

• 

  COVID-19 impact on physician compensation

  Healthcare provider organizations are facing financial and operational challenges as a result of COVID-19.

• 

  Medicare telehealth and COVID-19

  As demand for telehealth grows during the COVID-19 pandemic, CMS must consider what flexibilities can or should be extended.

• 

  Expansion of Telehealth in response to COVID-19

  Access to telehealth services in Medicare has been expanded in response to COVID-19, but those changes may not be permanent.

• 

  Don’t open the door to another threat

  Although healthcare organizations are focused on fighting COVID-19, the need for ongoing cyber security should not be underestimated.

• 

  Diagnostics: Ramp-up of testing for COVID-19 & beyond

  Private labs seeking to restructure or build to deploy COVID-19 testing operations can benefit from KPMG’s rapid start-up approach.

• 

  Promoting interoperability

  Virtual care is proving to be a critical tool in the fight against COVID-19. For more on how to get up and running

• 

  Restarting America – Practical Guide for Employers

  For businesses making decisions about when and how to reopen their businesses, here is a practical guide to key considerations.

• 

  Paycheck Protection Program and Health Care Enhancement Act

  Implications for Healthcare providers.

• 

  The critical role of health plans during and after COVID-19

  Health plans are seeking to address economic, workforce and remote member challenges during the COVID-19 outbreak; for more

• 

  Reaching the other side of COVID 19 part I

  A digital pathway

• 

  Reaching the other side of COVID 19 part II

  The power of data and emerging technology

• 

  HHS announces additional allocations for CARES Act provider relief funds

  HHS has announced plans to distribute the remaining $70 billion in CARES Act relief funds to providers; for more information

• 

  Healthcare providers: Pivoting the internal audit plan amidst COVID-19

  For guidance on how providers can pivot their internal audit plans to help give order to their organizations during COVID-19

• 

  Compliance can’t wait

  As healthcare providers battle COVID-19, they may need help balancing compliance obligations. For more on what to expect

• 

  Getting ahead of the surge

  For guidance on how to align supplies, medical personnel and clinical operations with the different stages of COVID-19

• 

  The time for virtual care is now

  Virtual care is proving to be a critical tool in the fight against COVID-19. For more on how to get up and running

• 

  Mobilizing for COVID-19

  For insight into how COVID-related payer guidelines and government regulations can impact the your revenue cycle

• 

  Part D senior savings model for insulin coverage

  CMS just announced alternative Part D options that lower seniors’ cost-sharing for insulin, according to the attached issue brief.

• 

  Recent CMS waivers and flexibility

  To learn how CMS is offering health systems greater flexibility and critical waivers during the COVID-19 crisis

• 

  Coding for COVID-19

  For an overview of how to navigate the new COVID-19 coding guidance, going into effect on April 1, 2020

• 

  Accelerated/advance payment for medicare providers and suppliers

  To learn more about enhancements to CMS’s Accelerated & Advance Payment Program to help providers & suppliers during COVID.

• 

  Coronavirus Aid, Relief, and Economic Security (CARES) Act

  Economic support and stimulus bill.

• 

  Living in an AI world - Healthcare insiders

  Taking the temperature of artificial intelligence in healthcare

• 

  The customer experience continuum

  Payers must join health systems and pharmaceutical manufacturers in efforts to improve customer experience.

• 

  2020 healthcare and life sciences investment outlook

  Analysis of the 2020 KPMG Healthcare and Life Sciences Investment Outlook survey sheds light on how the investment landscape will be impacted by influential disruptors, evolving market trends, and policy/regulatory developments.

• 

  On the 2020 healthcare audit committee agenda

  Prioritizing a heavy healthcare audit and compliance committee (audit committee) agenda is never easy, and 2020 will be particularly challenging.

• 

  On the 2020 healthcare board agenda

  Prioritizing a heavy healthcare board agenda is never easy, and 2020 will be particularly challenging.

• 

  Convenience: The new consumer healthcare imperative

  Patients have more choice than ever about where and when they seek care.

• 

  Healthcare 2030

  By 2030, a consumer-centric healthcare system will be an imperative. Here’s how to get there.

• 

  Revenue Cycle Automation

  The healthcare revenue cycle is ripe for productivity gains and cost reduction. Forward-reaching organizations are effecting real change with connected robotic process automation.